newsroom
Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19
Revive Therapeutics is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders.
ThermalPass and Internet of Things Inc. Featured on FOX.com
ThermalPass www.thermalpass.com, was prominently featured in an article on Fox.com last night titled, “As America reopens, fever-screening technology touted as promising tool.”
Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19
Revive Therapeutics is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders.
Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
We are advancing our main programs in COVID-19 and psychedelics with the aim to initiate clinical studies in the short-term while leveraging our assets and building our pharmaceutical-based product pipeline for long-term growth,” said Michael Frank, Revive’s Chief Executive Officer